

**DEPARTMENT OF HEALTH AND HUMAN SERVICES  
FOOD AND DRUG ADMINISTRATION**

|   |  |   |
|---|--|---|
| <small>DISTRICT ADDRESS AND PHONE NUMBER</small><br>Division of Biotechnology Manufacturing<br>10903 New Hampshire Avenue; White Oak Building 51<br>Room 2269, Silver Spring, MD 20993<br>E-mail: OPMABLAinspection483Responses@fda.hhs.gov |  | <small>DATE(S) OF INSPECTION</small><br>05/12/2023-05/22/2023 |
| <small>NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED</small><br>Alessandro Galassini, Site Director  |  | <small>FEI NUMBER</small><br>3002807108                       |
| <small>FIRM NAME</small><br>Sanofi S.p.A  | <small>STREET ADDRESS</small><br>Via Valcanello, 4                       |   |
| <small>CITY, STATE, ZIP CODE, COUNTRY</small><br>Anagni, FR, Italy, 03012   | <small>TYPE ESTABLISHMENT INSPECTED</small><br>Drug Product Manufacturer |   |

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

**OBSERVATION 1**

**Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed. Specifically,**

- a) the setup of the sterilized stopper bowl and parts in the (b) (4) is not performed aseptically. With open (b) (4) each piece of the (b) (4) stopper bowl assembly is exposed to Iso8 air, prior to its installation in the (b) (4). Once the stopper bowl is setup, the equipment is cleaned, the (b) (4) are closed, and the (b) (4) is decontaminated with (b) (4).
- b) the process of making an aseptic connection between the (b) (4) and the (b) (4) is performed using non-sterile (b) (4) gloves. In addition, during this operation the (b) (4) gloves were blocking first air on exposed sterile (b) (4).
- c) during setup installation of the sterilized (b) (4) I observed the operator touch the sterile unprotected tubing end with (b) (4) gloves both during removal of the (b) (4) from the (b) (4) bag and during its installation.
- d) vials that are to be rejected due to an intervention are not immediately discarded/undergo line clearance. Rather, the to be rejected vials are transferred to the (b) (4) and (b) (4) with the acceptable vials. No formal risk assessment of this practice regarding the potential for cross-contamination between acceptable and rejected vials was provided at the start of the inspection.
- e) during manufacturing of batch (b) (4) I observed a stopper bowl intervention where the operator blocked first air on sterile stoppers with his (b) (4) gloves.
- f) the sterility of sterilized equipment used during setup and manufacturing is not maintained due to handling with (b) (4) gloves.

|                          |   |   |   |
|--------------------------|---|---|---|
| SEE REVERSE OF THIS PAGE | <small>EMPLOYEE(S) SIGNATURE</small><br> | <small>EMPLOYEE(S) NAME AND TITLE (Print or Type)</small><br>Richard Ledwidge, Senior Biologist | <small>DATE ISSUED</small><br>May 22, 2023<br>May 21, 2023 RL |
|--------------------------|---|---|---|

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
FOOD AND DRUG ADMINISTRATION

DISTRICT ADDRESS AND PHONE NUMBER

Division of Biotechnology Manufacturing  
10903 New Hampshire Avenue; White Oak Building 51  
Room 2269, Silver Spring, MD 20993  
E-mail: OPMABLAinspection483Responses@fda.hhs.gov

DATE(S) OF INSPECTION

05/12/2023-05/22/2023

FEI NUMBER

3002807108

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED

Alessandro Galassini, Site Director

FIRM NAME

Sanofi S.p.A

STREET ADDRESS

Via Valcanello, 4

CITY, STATE, ZIP CODE, COUNTRY

Anagni, FR, Italy, 03012

TYPE ESTABLISHMENT INSPECTED

Drug Product Manufacturer

**OBSERVATION 2**


**Aseptic process simulations do not fully represent drug product manufacturing in the** (b) (4)  
**Specifically,**

The firm does not use (b) (4) used in production for any products filled in the (b) (4)  
Rather, all (b) (4) aseptic simulations are conducted with like-for-like (b) (4) dedicated  
solely to media fills.

APPEARS  
THIS WAY ON  
ORIGINAL

SEE  
REVERSE  
OF THIS  
PAGE

EMPLOYEE(S) SIGNATURE



EMPLOYEE(S) NAME AND TITLE (Print or Type)

Richard Ledwidge, Senior Biologist

DATE ISSUED

May 22, 2023  
~~May 21, 2023~~

RL